Michael Thase, MD

Patient-Reported Effects of Adjunctive Brexpiprazole on Calming and Engagement in Major Depressive Disorder: Post Hoc Analysis of Clinical Trial Exit Interviews

Background: Calming patients (without sedation) and increasing engagement (without overactivation) are important components of the successful treatment of major depressive disorder (MDD)....

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Catherine Gupta , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

T. Michelle Brown , PhD;

10/08/2020

A Buprenorphine-Samidorphan Combination (BUP/SAM) for Adjunctive Treatment of Major Depressive Disorder: Results From Analyses of US Patients From Three Placebo-Controlled Trials

Background: Buprenorphine/samidorphan (BUP/SAM) is an investigational opioid system modulator for adjunctive treatment of major depressive disorder. To account for differences in treatmen...

William Martin , PhD;

Elliot Ehrich , MD;

Michael Thase , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

Amy Claxton , PhD;

Sanjeev Pathak , MD;

Arielle Stanford , MD;

Asli Memisoglu , ScD;

02/28/2019

Effect of Adjunctive Pimavanserin on Insomnia and Function in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY

Up to 90% of patients with major depressive disorder (MDD) experience sleep disturbances. CLARITY was a phase 2 study of adjunctive pimavanserin, a 5-hydroxytryptamine2A antagonist/invers...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

Manish Jha ;

Maurizio Fava , MD, PhD;

Marlene Freeman , MD;

Madhukar Trivedi , MD;

George Papakostas , MD;

Srdjan Stankovic , MD, MSPH;

10/08/2020

Efficacy of Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Partial Response to Antidepressant Treatment: a Post Hoc Analysis of Three Randomized Studies

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT), which are associated wit...

Michael Thase , MD;

Liz Kelly ;

01/19/2023

Efficacy of Adjunctive Brexpiprazole in Adults With MDD: Improvement of Patient Engagement Based on Selected Items From the Inventory of Depressive Symptomatology Self-Report (IDS-SR) Scale

Objective: These post-hoc analyses used relevant items from the IDS-SR to explore whether treatment with adjunctive brexpiprazole in patients with MDD has potential to improve a new conce...

Anne Pedersen , MSc;

Klaus Groes Larsen , PhD;

Anna-Greta Nylander , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Roger McIntyre , MD, FRCPC;

11/22/2019

Efficacy of Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who Are Early in the Disease Course: a Post Hoc Analysis of Four Randomized Studies

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT). For such patients, early...

Michael Thase , MD;

Liz Kelly ;

01/19/2023

Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin

Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY...

Srdjan Stankovic , MD, MSPH;

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Bryan Dirks , MD, MSc, MBA;

Manish Jha ;

Marlene Freeman , MD;

George Papakostas , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

11/22/2019

Combinatorial Pharmacogenomic Testing Improves Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized, Controlled Trial

Objectives: The GUIDED trial demonstrated that combinatorial pharmacogenomic (PGx) testing significantly improved the rate of response (p=0.007) and remission (p=0.005) and approached sig...

John Greden , MD;

Anthony Rothschild , MD;

Michael Thase , MD;

Boadie Dunlop , MD;

Richard Shelton , MD;

Charles Conway , MD;

Lisa Brown , PhD;

Jennie Depatie , PhD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Matthew Macaluso , DO;

Krystal Brown , PhD;

Michael J. Crescenz ;

Michael Jablonski , PhD;

Charles DeBattista , MD;

Sagar Parikh , MD;

11/22/2019

Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials

Purpose: To evaluate the impact of esketamine (ESK) nasal spray in patients with treatment-resistant depression (TRD) and comorbid anxiety.

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Stephane Borentain , MD;

Madhukar Trivedi , MD;

Michael Thase , MD;

Jaskaran Singh , MD;

Giacomo Salvadore , MD;

Maggie Fedgchin , PharmD;

H. Lynn Starr , MD, FAAP;

A. John Rush , MD;

11/22/2019

CLARITY: A Phase 2 Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

This study examined pimavanserin (PIM), a 5-HT2A receptor inverse agonist/antagonist, as a potential adjunct to SSRIs or SNRIs for major depressive disorder (MDD). Adult female and male p...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

Marlene Freeman , MD;

George Papakostas , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

Srdjan Stankovic , MD, MSPH;

11/22/2019